📚 Lecture Overview
This lecture covers Myeloproliferative Neoplasms (MPNs), a heterogeneous group of clonal hematopoietic stem cell disorders characterized by the excessive proliferation of myeloid, erythroid, or megakaryocytic cell lineages. Understanding these disorders is clinically crucial because they involve constitutive tyrosine kinase activation—primarily driven by the JAK2 gene mutation—and carry risks of thrombosis, hemorrhage, and leukemic transformation. The lecture details three primary conditions: Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (PMF).
🎯 Key Concepts & Definitions
- Myeloproliferative Neoplasms (MPNs): Clonal hematopoietic stem cell neoplasms featuring excessive proliferation of one or more blood cell lineages with relatively normal maturation.
- JAK2 Gene: A gene encoding a protein tyrosine kinase in the JAK/STAT signaling pathway that transmits growth and proliferation signals for blood cell production.
- Polycythemia Vera (PV): A clonal bone marrow malignancy characterized by an absolute increase in red cell mass (panmyelosis) and high frequency of the JAK2 mutation.
- Essential Thrombocythemia (ET): The most common MPN, characterized by sustained peripheral blood thrombocytosis ($≥ 450 × 10^9/L$) and abnormal megakaryocyte proliferation.
- Primary Myelofibrosis (PMF): An MPN defined by progressive generalized bone marrow fibrosis and extramedullary hematopoiesis in the spleen and liver, carrying the worst prognosis.
- Leukoerythroblastosis: The presence of immature red and white blood cell precursors in the peripheral blood, commonly seen in PMF alongside tear-drop red blood cells.
📖 Main Content
1. The JAK2 Mutation & Pathogenesis
- Constitutive tyrosine kinase activation is the core pathogenetic mechanism underlying MPNs.
- The JAK2 gene regulates the JAK/STAT pathway, transmitting extracellular chemical signals to the cell nucleus to control hematopoietic stem cell proliferation.
- JAK-2 mutation incidence varies by specific disorder: present in $>90%$ of PV cases and roughly $60%$ of ET and PMF cases.
2. Polycythemia Vera (PV)
- Definition: Clonal malignancy leading to increased red cell mass, often accompanied by overproduction of granulocytes and platelets.
- Causes of Erythrocytosis:
- Absolute (increased red cell mass):
- Primary: Polycythemia Vera.
- Secondary (Appropriate EPO): Pulmonary disease, congenital cyanotic heart disease, high-affinity hemoglobin, heavy smoking.
- Secondary (Inappropriate EPO): Renal disorders (hydronephrosis, cysts, renal cell carcinoma), uterine fibromyoma, hepatocellular carcinoma, cerebellar hemangioblastoma.
- Relative / Pseudo-polycythemia: Normal red cell mass with reduced plasma volume due to dehydration or plasma loss (burns).
- Clinical Features: Driven by hyperviscosity, hypervolemia, and hypermetabolism.
- Headaches, blurred vision, night sweats, and pruritus characteristically after a hot bath.
- Erythromelalgia: Burning sensation in fingers and toes with erythema or cyanosis.
- Splenomegaly ($70%$) and hepatomegaly ($40%$).
- Arterial or venous thrombosis ($40%$) and hemorrhage ($20%$).
- WHO Diagnostic Criteria:
- Major: $Hb > 16.5 g/dL$ (men) / $16.0 g/dL$ (women) OR $Hct > 49%$ (men) / $48%$ (women) OR increased red cell mass; Bone marrow biopsy showing hypercellularity with trilineage growth; Presence of JAK2 mutation.
- Minor: Subnormal serum EPO level.
- Diagnosis: All 3 major criteria, OR the first 2 major criteria plus the minor criterion.
- Treatment Strategies:
- Venesection: Target $Hct < 45%$ for males, $< 42%$ for females.
- Aspirin: $75-100 mg$ daily for thrombosis prevention.
- Cytotoxic myelosuppression: Hydroxyurea or intermittent busulphan (avoided in younger patients due to leukemia risk).
- Phosphorus-32 ($^{32}P$): Beta-emitter concentrated in bone, used for older patients.
- Interferon-$\alpha$ and JAK2 inhibitors (Ruxolitinib).
3. Essential Thrombocythemia (ET)
- Overview: The most common MPN, affecting older adults (median age ~60) with a female predominance ($1.5–2$-fold).
- WHO Diagnostic Criteria:
- Major: Platelet count $≥ 450 × 10^9/L$; Bone marrow biopsy showing proliferation of enlarged, mature megakaryocytes with hyperlobulated nuclei; Not meeting criteria for CML, PV, or PMF; Presence of JAK2 mutation.
- Minor: Presence of a clonal marker or absence of reactive thrombocytosis.
- Diagnosis: All 4 major criteria, OR the first 3 major criteria plus one minor criterion.
- Reactive Thrombocytosis Differentials: Iron deficiency, acute/chronic blood loss, postsurgery, hyposplenism, chronic inflammation, malignancy, and rebound recovery.
- Clinical Features: Vasomotor symptoms (headaches, visual changes, erythromelalgia), arterial/venous thrombosis, hemorrhagic tendencies, and obstetric complications (first-trimester spontaneous abortion).
- Treatment & Risk Stratification:
- High-risk ($≥ 60$ years or history of thrombosis/extreme thrombocytosis): Treated with cytoreductive therapy like Hydroxyurea to maintain platelets $< 400 × 10^9/L$.
- Low-risk ($< 40$ years without high-risk features): Low-dose aspirin alone.
- Second-line agents include Anagrelide and $\alpha$-interferon.
4. Primary Myelofibrosis (PMF)
- Pathophysiology: Progressive generalized bone marrow fibrosis secondary to megakaryocyte-derived platelet-derived growth factor (PDGF) stimulating fibroblasts, paired with extramedullary hematopoiesis in the spleen and liver.
- WHO Diagnostic Criteria:
- Major: Megakaryocytic proliferation and atypia with reticulin/collagen fibrosis; Exclusion of other myeloid neoplasms; Presence of JAK2 mutation.
- Minor: Anemia, leukocytosis $> 11 × 10^9/L$, palpable splenomegaly, elevated LDH, or leukoerythroblastosis.
- Diagnosis: All 3 major criteria plus minor criteria.
- Clinical & Laboratory Features:
- Insidious onset with prominent anemia and massive splenomegaly causing abdominal discomfort.
- Hypermetabolic symptoms (weight loss, fever, night sweats).
- Peripheral blood shows tear-drop poikilocytes and leukoerythroblastosis.
- Bone marrow aspiration typically yields a "dry tap" due to fibrosis.
- Treatment:
- Palliative management: Blood transfusions, folic acid, hydroxyurea for splenomegaly, and allopurinol for hyperuricemia.
- Allogeneic stem cell transplantation is the only curative treatment for young patients.
- Splenectomy or splenic irradiation for severe symptomatic splenomegaly.
📊 Visual Learning
💡 Important Points to Remember
- MPNs feature excessive blood cell proliferation with relatively normal maturation driven by constitutive tyrosine kinase activation.
- The JAK2 mutation is present in $>90%$ of Polycythemia Vera cases and about $60%$ of ET and PMF cases.
- Polycythemia Vera diagnostic hallmarks include elevated hemoglobin/hematocrit, panmyelosis on bone marrow biopsy, a mutated JAK2, and subnormal serum EPO levels.
- Pruritus characteristically provoked by a hot bath is a classic clinical clue for Polycythemia Vera.
- The therapeutic target for hematocrit in PV management is $<45%$ for males and $<42%$ for females.
- Essential Thrombocythemia requires a platelet threshold of $≥ 450 × 10^9/L$ alongside exclusion of reactive thrombocytosis and CML.
- Primary Myelofibrosis presents with a bone marrow "dry tap", tear-drop red blood cells, leukoerythroblastosis, and massive splenomegaly.
- Allogeneic stem cell transplantation is the sole curative modality for Primary Myelofibrosis.
- Hydroxyurea serves as a core cytoreductive agent across multiple MPNs to control counts and mitigate thrombotic risk.
- Prognostic order (Best to Worst): ET has the best prognosis, followed by PV, with PMF carrying the worst prognosis and highest risk of acute myeloid leukemia transformation.
⚠️ Common Exam Questions
Examiners frequently test the differentiation between primary and secondary causes of erythrocytosis and thrombocytosis. A classic multiple-choice trap is presenting a patient with high hemoglobin and asking for the diagnosis without checking the serum EPO level or recognizing secondary physiological compensations (e.g., chronic smoking or hypoxia). Another common trap involves confusing reactive thrombocytosis (caused by iron deficiency, inflammation, or post-splenectomy) with Essential Thrombocythemia; examiners will omit molecular markers or bone marrow biopsy findings to see if students jump to conclusions based purely on an elevated platelet count. Additionally, questions frequently test why Busulphan or Phosphorus-32 are avoided in younger patients (due to long-term leukemic transformation risks).
📝 Quick Review Checklist
I can explain the core role of the JAK2 gene and JAK/STAT pathway in MPNs
I understand the major and minor diagnostic criteria for Polycythemia Vera
I can differentiate between absolute and relative polycythemia causes
I know the diagnostic threshold and clinical features of Essential Thrombocythemia
I can distinguish ET from causes of reactive thrombocytosis
I understand the pathogenesis of bone marrow fibrosis and extramedullary hematopoiesis in PMF
I recognize peripheral blood findings like tear-drop cells and leukoerythroblastosis
I know the primary treatment modalities and curative options for each MPN